Insys Therapeutics, Inc. (NASDAQ:INSY)

Friday, August 22, 2014 | Web News
On August 11, 2014, we released the following: As we have been closely following the hot cannabis industry, we noticed two companies that are working...
See All Research...
Monday, August 11, 2014, 9:25 AM
The Long And Short Of It: Buy Insys Therapeutics And Sell GW Pharmaceuticals
See All Articles and Reports...
Insys Therapeutics, Inc., a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients; and Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. It offers its Subsys through its incentive-based commercial sales force. The company also provides Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Insys Therapeutics, Inc. was incorporated in 1990 and is headquartered in Chandler, Arizona.

Web site: http://www.insysrx.com

Last updated August 11, 2014